Clinical Trials Logo

Mast Cell Activation Syndrome clinical trials

View clinical trials related to Mast Cell Activation Syndrome.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05449444 Recruiting - Clinical trials for Mast Cell Activation Syndrome

Masitinib for the Treatment of Severe Mast Cell Activation Syndrome

Start date: July 1, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of two dosing schemes of oral masitinib versus matching placebo in the treatment of patients suffering from severe MCAS with handicap unresponsive to optimal symptomatic treatment.

NCT ID: NCT04910685 Recruiting - Clinical trials for Indolent Systemic Mastocytosis

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Start date: November 30, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of BLU-263 + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by BSC. Parts 1 and 2 will enroll patients with ISM. Patients enrolled in Part 1 or Part 2 will roll over onto Part 3 to receive treatment with BLU-263 in an open-label fashion following completion of the earlier Part. Part M will enroll patients with monoclonal mast cell activation syndrome (mMCAS). The study also includes PK groups that will enroll patients with ISM.